Russia will simplify the procedure for imports of unregistered drugs against serious diseases starting from March of next year, according to recent statements by state authorities and local media reports.
Both public funds and medical organizations will be able to conduct imports through State Services, Russia’s major reference and information Internet portal (site). That will affect drugs that are not registered in Russia and have no domestic analogues.
Previously, there was no clear regulation for such imports, the permission for which was coordinated with the Federal Service for Surveillance in Healthcare (Roszdravnadzor) in each specific case, which led to serious delays in supplies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze